Avishek, Kumar
Beg, Mirza A.
Vats, Kavita
Singh, Avinash Kumar
Dey, Ranadhir
Singh, Kamaleshwar P.
Singh, Rajesh Kumar
Gannavaram, Sreenivas
Ramesh, V.
Mulla, Mohmad Sadik A.
Bhatnagar, Upendra
Singh, Sanjay
Nakhasi, Hira L.
Salotra, Poonam
Selvapandiyan, Angamuthu
Funding for this research was provided by:
Biotechnology Industry Research Assistance Council, India (BT/CRS02l 4/CRS-1 0/l 6)
Article History
Received: 17 December 2023
Accepted: 11 June 2024
First Online: 25 June 2024
Competing interests
: The US-FDA is currently a co-owner of two US patents that claim attenuated <i>Leishmania</i> species with the Centrin gene deletion (US 7,887,812 and US 8,877,213). All other authors declare they have no competing interests.